Skip to main content

Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma (Valemetostat tosylate [DS-3201b], an enhancer of zeste homolog [EZH] 1/2 dual inhibitor, for R/R PTCL)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Daiichi Sankyo Inc

Start Date

April 5, 2022

End Date

March 27, 2027
 

Administered By

Duke Cancer Institute

Awarded By

Daiichi Sankyo Inc

Start Date

April 5, 2022

End Date

March 27, 2027